Practitioner's Docket No. MPI1995-001CP1CP1CN1M

USSN: 10/067,741

IN THE SPECIFICATION

At page 120, please amend the abstract beginning at line 9 as follows:

The present invention relates to methods and compositions for the treatment and diagnosis of but not limited to, atherosclerosis, cardiovascular disease, including, rupture, ischemia/reperfusion, hypertension, atherosclerosis/plaque cardiac calcification, allo/xenograft valvular calcifications, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Furtherthe present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the officacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various eardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. Moreover, the present invention is further based in part on the generation and phenotypic characterization of transgenic knockout homozygous rchd534 mutant mice which display characteristic cardiovascular disease symptoms. Such transgenic knockout homozygous rchd534 mutant mice are useful models for the analysis and characterization of rchd534 protein involvement in development and homeostasis of the cardiovascular system and tissue-specific regulation of the TGF-B signaling pathways.